Florbetapir positron emission tomography and cerebrospinal fluid biomarkers

Alzheimer's & Dementia - Tập 11 - Trang 986-993 - 2015
Ann Hake1,2, Paula T. Trzepacz1,3, Shufang Wang1, Peng Yu1, Michael Case1, Helen Hochstetler1, Michael M. Witte1, Elisabeth K. Degenhardt1,3,4, Robert A. Dean1
1Eli Lilly and Company, Indianapolis, IN, USA
2Department of Neurology; Indiana University School of Medicine; Indianapolis, IN USA
3Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA
4Indiana University Health Physicians Group, Indiana University Health, Indianapolis, IN, USA

Tóm tắt

AbstractBackgroundWe evaluated the relationship between florbetapir‐F18 positron emission tomography (FBP PET) and cerebrospinal fluid (CSF) biomarkers.MethodsAlzheimer's Disease Neuroimaging Initiative‐Grand Opportunity and Alzheimer's Disease Neuroimaging Initiative 2 (GO/2) healthy control (HC), mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia subjects with clinical measures and CSF collected ±90 days of FBP PET data were analyzed using correlation and logistic regression.ResultsIn HC and MCI subjects, FBP PET anterior and posterior cingulate and composite standard uptake value ratios correlated with CSF amyloid beta (Aβ1–42) and tau/Aβ1–42 ratios. Using logistic regression, Aβ1–42, total tau (t‐tau), phosphorylated tau181P (p‐tau), and FBP PET composite each differentiated HC versus AD. Aβ1–42 and t‐tau distinguished MCI versus AD, without additional contribution by FBP PET. Total tau and p‐tau added discriminative power to FBP PET when classifying HC versus AD.ConclusionBased on cross‐sectional diagnostic groups, both amyloid and tau measures distinguish healthy from demented subjects. Longitudinal analyses are needed.

Tài liệu tham khảo

10.1017/S0317167100015547 10.1097/NEN.0b013e31824b211b 10.1016/S1474-4422(12)70142-4 10.1093/cercor/bhr271 10.1002/ana.20730 10.1007/s12031-011-9665-5 10.1016/j.jalz.2011.07.004 TeunissenCE VerweyNA KesterMI vanUffelenK BlankensteinMA.Standardization of assay procedures for analysis of the CSF biomarkers amyloid beta((1–42)) tau and phosphorylated tau in Alzheimer's disease: report of an international workshop.Int J Alzheimers Dis2010https://doi.org/10.4061/2010/635053 10.1016/S1474-4422(12)70291-0 10.1016/j.jalz.2014.02.004 VergaraC Ordóñez‐GutiérrezL WandosellF FerrerI Del RioJA GavinR.Role of PrP expression in tau protein levels and phosphorylation in Alzheimer's disease evolution.Mol Neurobiol2014https://doi.org/10.1007/s12035‐014‐8793‐7[Epub ahead of print] 10.1186/1750-1326-9-22 10.1001/archneur.64.3.noc60123 10.1097/NEN.0b013e31822e8ae9 10.1016/S1474-4422(13)70044-9 10.1016/j.nicl.2013.07.005 Temple V, 2001, Alzheimer dementia in Down's syndrome: the relevance of cognitive ability, J Intellect Disabil Res, 45, 47, 10.1111/j.1365-2788.2001.00299.x 10.1177/153331750101600606 10.1159/000329542 10.1097/01.nrl.0000252947.15389.a9 10.1097/NEN.0b013e3181d8db07 10.1001/archneurol.2011.150 Holm S, 1979, A simple sequentially rejective multiple test procedure, Scand J Stat, 6, 65 10.1001/archgenpsychiatry.2011.155 Thomann PA, 2009, Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease, J Psychiatry Neurosci, 34, 136 10.1097/WCO.0b013e32835a30f4 10.1007/s00401-013-1139-0 Doré V, 2013, Cross‐sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease, JAMA Neurol, 70, 1, 10.1001/jamaneurol.2013.1062 10.1001/archneurol.2011.183 10.1016/j.neurobiolaging.2009.12.008 10.1001/archneurol.2011.3029
Thông tin
Thông tin xuất bản

Alzheimer's & Dementia

Tập 11

986-993

Thông tin tác giả